Patents Assigned to Affimed GMBH
-
Patent number: 11572415Abstract: The application pertains to a trispecific antibody molecule which may comprise a diabody-unit integrated into a polypeptide chain having at least six variable domains linked one after another. In certain instances two single-chain Fv (scFv) fragments are distally connected to the diabody-unit providing two further antigen binding sites (FIGS. 1 and 2).Type: GrantFiled: April 11, 2018Date of Patent: February 7, 2023Assignee: AFFIMED GMBHInventors: Kristina Ellwanger, Ivica Fucek, Thorsten Ross, Thomas Mueller, Erich Rajkovic, Uwe Reusch, Martin Treder, Michael Weichel
-
Patent number: 11535672Abstract: The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.Type: GrantFiled: July 24, 2019Date of Patent: December 27, 2022Assignee: AFFIMED GMBHInventors: Joachim Koch, Martin Treder, Jens Pahl, Uwe Reusch, Thorsten Ross, Erich Rajkovic, Adelheid Cerwenka
-
Patent number: 11510972Abstract: Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.Type: GrantFiled: September 2, 2020Date of Patent: November 29, 2022Assignee: AFFIMED GMBHInventors: Michael Kluge, Michael Tesar, Ivica Fucek, Kristina Ellwanger, Uwe Reusch, Michael Damrat, Erich Rajkovic, Martin Treder
-
Patent number: 11180558Abstract: The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCM.Type: GrantFiled: July 23, 2019Date of Patent: November 23, 2021Assignee: Affimed GMBHInventors: Thorsten Ross, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Uwe Reusch, Stefan Knackmuss, Erich Rajkovic, Martin Treder
-
Patent number: 11167029Abstract: Described is a combination therapy of (i) a multifunctional antibody having specificity for CD30 and CD16A and (ii) an anti-PD-1 antibody for the treatment of a tumor, in particular Hodgkin lymphoma.Type: GrantFiled: October 19, 2017Date of Patent: November 9, 2021Assignee: AFFIMED GMBHInventors: Martin Treder, Uwe Reusch, Jens-Peter Marschner, Stefan Knackmuss
-
Publication number: 20210253698Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA)expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: ApplicationFiled: April 20, 2021Publication date: August 19, 2021Applicant: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Patent number: 11001633Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: GrantFiled: December 13, 2019Date of Patent: May 11, 2021Assignee: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Publication number: 20200109202Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA)expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: ApplicationFiled: December 13, 2019Publication date: April 9, 2020Applicant: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Patent number: 9701750Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: GrantFiled: April 20, 2015Date of Patent: July 11, 2017Assignee: Affimed GmbHInventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
-
Patent number: 9226962Abstract: Described are mono- and multivalent scFv-antibodies comprising the binding sites specific for the human T cell marker CD3. These antibodies are strongly immunosuppressive and do not cause a significant release of cytokines. Furthermore, polynucleotides encoding said antibodies are described as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Pharmaceutical compositions containing any of the above mentioned polynucleotides, antibodies or vectors are useful for immunotherapy, preferably against acute transplant rejections.Type: GrantFiled: January 11, 2013Date of Patent: January 5, 2016Assignee: AFFIMED GMBHInventors: Fabrice Le Gall, Sergey Kipriyanov, Melvin Little, Uwe Reusch
-
Patent number: 9035026Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: GrantFiled: May 26, 2006Date of Patent: May 19, 2015Assignee: Affimed GMBHInventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch